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Alternative splicing of the human glucocorticoid re-
ceptor (hGR) primary transcript produces two receptor
isoforms, hGRa and hGRb, which differ at their car-
boxyl termini. The hGRa isoform conveys endocrine in-
formation to target tissues by altering patterns of gene
expression in a hormone-dependent fashion. In contrast
to hGRa, very little is known about the hGRb splice
variant. Using hGRa- and hGRb-specific riboprobes on
human multiple tissue Northern blots, we show that the
hGRb message has a widespread tissue distribution. We
also prove by reverse transcriptase-polymerase chain
reaction that the alternative splicing event underlying
the formation of the hGRb message occurs in these tis-
sues. Because the hGRb protein differs from hGRa at the
extreme COOH terminus, we investigated several of the
biochemical properties of hGRb expressed in trans-
fected cells. hGRb does not bind the glucocorticoid ag-
onist dexamethasone nor the glucocorticoid antagonist
RU38486 in vivo. Moreover, in contrast to hGRa, hGRb is
located primarily in the nucleus of transfected cells in-
dependent of hormone administration. Finally, in the
absence of hGRa, hGRb is transcriptionally inactive on
a glucocorticoid-responsive enhancer. However, when
both isoforms are expressed in the same cell, hGRb in-
hibits the hormone-induced, hGRa-mediated stimula-
tion of gene expression. Thus, hGRb potentially func-
tions as a dominant negative inhibitor of hGRa activity.
Two human glucocorticoid receptor (hGR)1 cDNA clones,
termed hGRa and hGRb, were isolated in 1985 that predicted
the existence of two receptor isoforms differing at their car-
boxyl termini (1). Amino acid sequence analysis revealed that
the hGRa and hGRb isoforms were identical through amino
acid 727 but diverged beyond this position with hGRa having
an additional 50 amino acids and hGRb an additional, nonho-
mologous 15 amino acids. Exons 1–8 of the hGR gene contain
the 59 noncoding and coding sequences common to the hGRa
and hGRb cDNAs, and exons 9a and 9b contain the coding and
39 noncoding sequences specific to the hGRa and hGRb cDNAs
(2). Because the hGRa- and hGRb-specific sequences are lo-
cated on the same gene, alternative splicing of exons 9a and 9b
was speculated to be the mechanism responsible for generating
the two receptor isoforms. However, initial Western blot anal-
ysis detected only the larger 94-kDa hGRa isoform, and only
hGRa appeared to bind hormone and induce expression of a
glucocorticoid-responsive reporter plasmid in a hormone-de-
pendent manner (1, 3). Because of its predominant expression,
ligand binding properties, and transcriptional activity, hGRa
became the primary focus of subsequent research. As a result,
its expression, biochemical properties, and physiological func-
tion have been well characterized.
hGRa is expressed in most human tissues and cell lines and
belongs to the superfamily of steroid/thyroid/retinoic acid re-
ceptor proteins that function as ligand-dependent transcription
factors (for reviews see Refs. 4–6). Members of this family are
organized into structurally and functionally defined domains.
Specifically, hGRa is comprised of a unique amino-terminal
variable region that includes a transactivation domain that is
important for regulation of gene expression. hGRa also con-
tains a central DNA-binding domain crucial for specific inter-
action of the receptor with DNA sequences containing glucocor-
ticoid receptor responsive elements (GRE). The carboxyl
terminus of the hGRa protein contains the hormone-binding
domain as well as sequences important for interaction with
heat shock protein 90 (hsp90) (7), nuclear translocation (8),
receptor dimerization (9), and transactivation (10).
In the absence of hormone, hGRa resides predominantly in
the cytoplasm of cells, where it exists as a large multiprotein
complex (for reviews see Refs. 11 and 12). This complex appears
to consist of the receptor polypeptide, two molecules of hsp90,
and several additional proteins. The association of hsp90 with
the receptor is believed to maintain the receptor in a high
affinity hormone binding state and sequester the receptor in
the cytoplasm by inactivating the nuclear localization signals
(NLS). Once hormone binds the receptor, a conformational
change ensues resulting in the dissociation of hsp90 and the
other associated proteins. In its new conformation hGRa trans-
locates into the nucleus, where it binds as a homodimer to
GREs that are usually found in the promoter regions of steroid-
responsive genes. The receptor then communicates with the
basal transcription machinery to either enhance or repress
transcription of the linked gene. hGRa can also modulate gene
expression by physically interacting with other nuclear pro-
teins such as AP-1 (13–15) and NF-kB (16).
In contrast to hGRa, very little is known about the physio-
logical significance of hGRb. We demonstrate here that a
mRNA transcript consistent in size with the hGRb cDNA is
expressed in various human adult and fetal tissues and in
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several transformed human cell lines. We also confirm that the
alternative splicing event underlying the formation of the
hGRb message occurs in these tissues. In addition, we show
that the unique COOH-terminal end of hGRb influences sev-
eral key biochemical properties of this isoform that distin-
guishes it from hGRa. We demonstrate that hGRb does not
bind glucocorticoids or antiglucocorticoids in vivo, resides in
the nucleus independent of hormone administration, and in the
absence of hGRa is transcriptionally inactive on a glucocorti-
coid-responsive enhancer. It was recently reported that trans-
fected hGRb inhibits transfected hGRa-mediated induction of
the mouse mammary tumor virus (MMTV) promoter (17). We
extend these findings by demonstrating that hGRb represses
the activity of endogenous hGRa and that this hGRb-mediated
repression is a general phenomenon of glucocorticoid-respon-
sive promoters. Thus, the physiological significance of hGRb
may reside in its ability to antagonize the function of hGRa.
EXPERIMENTAL PROCEDURES
Materials—Dexamethasone (DEX) was obtained from Steraloids
(Wilton, NH). [3H]DEX (48.2 Ci/mmol) and [14C]chloramphenicol
(40–60 mCi/mmol) were obtained from DuPont NEN. RU38486
(RU486) and [3H]RU486 (50.6 Ci/mmol) were kindly provided by Dr. R.
Deraedt, Roussel-UCLAF (Romainville, France). [a-32P]UTP (3000 Ci/
mmol) was purchased from ICN Radiochemical. The murine leukemia
virus reverse transcriptase, AmpliTaq DNA polymerase, deoxynucle-
otide triphosphates, MgCl2, and the RT-PCR buffers were purchased
from Perkin-Elmer. Acetyl coenzyme A was obtained from Boehringer
Mannheim, and thin layer chromatography sheets were from EM
Separations.
Recombinant Plasmids—The hGRa expression vector pCYGR (by Y.
Itoh-Lindstrom and J. A. Cidlowski) served as the vector for the expres-
sion plasmids pCMVhGRa and pCMVhGRb utilized in this study.
pCYGR was constructed by isolating the 3.0-kb KpnI–XhoI cDNA frag-
ment of pRShGRa (3). This fragment (which includes the entire hGRa
coding region and the first 384 bp of the hGRa 39UTR) was then cloned
downstream of the human cytomegalovirus major intermediate early
gene promoter region in the plasmid pCMV5 (18). The hGRa expression
vector pCMVhGRa was constructed by isolating the 3.3-kb ClaI–
BamHI cDNA fragment from the hGRa clone OB7 (1). This fragment
(which contains the distal 940 bp of the hGRa coding region and the
2322 bp hGRa 39UTR) was then cloned into the ClaI–BamHI sites in
pCYGR. The hGRb expression vector pCMVhGRb was constructed by
isolating the 2.3-kb ClaI–BamHI cDNA fragment from the hGRb clone
OB10 (1). This fragment (which contains the hGRb-specific coding
sequences as well as the 1430-bp hGRb 39UTR) was then cloned into the
ClaI–BamHI sites in pCYGR. Plasmids pGMCS (19), pGRE2CAT (20),
and pBLCAT2 (21) have been previously described.
Cell Culture and Transfections—HeLa S3 and COS-1 cells were
grown as described previously (22, 23). CV-1 cells were grown in Dul-
becco’s minimum essential medium supplemented with 2 mM glutamine
and 10% (v/v) heat-inactivated fetal calf serum. CEM-C7 cells were
grown in suspension in RPMI 1640 medium supplemented with 2 mM
glutamine and 10% (v/v) heat-inactivated fetal calf serum. All cultures
were maintained in a 5% CO2 humidified atmosphere at 37 °C and were
passaged every 3–4 days. HeLa S3 and COS-1 cells were transfected
essentially as described previously (22). Briefly, 4 h before transfection,
medium was replaced with fresh Dulbecco’s minimum essential me-
dium containing 3% serum. Plasmid DNA was prepared as a calcium
phosphate precipitate and incubated with cells for 5 h followed by a 30-s
shock with 15% glycerol. Cells were then refed supplemented medium.
Northern Blots—Human adult and fetal multiple tissue Northern
blots were purchased from ClonTech (Palo Alto, CA). Membranes were
prehybridized and hybridized at 65 °C in 50% formamide, 5 3 SSPE, 5
3 Denhardt’s solution, 2% SDS, 200 mg/ml yeast RNA, 200 mg/ml
denatured sheared salmon sperm DNA. 32P-Labeled antisense RNA
probes (1 3 106 cpm/ml hybridization fluid) were generated from a
T3/T7 promoter-containing vector containing the distal hGRa 39UTR
(537-bp PstI–KpnI fragment from the hGRa clone OB7), the hGRb
coding and proximal 39UTR (581-bp NsiI–SstI fragment from the hGRb
clone OB10), or the entire hGRa coding region (;3-kb KpnI–XhoI
fragment from the hGRa expression vector pRShGRa). Following hy-
bridization, blots were washed once at room temperature and four times
at 65 °C in 0.1 3 SSPE, 0.1% SDS. The blots were then exposed to x-ray
film. Membranes were stripped of radioactivity for 30 min in 0.1 3
SSPE, 0.1% SDS heated to 100 °C before reprobing.
RT-PCR— Human liver and lung total RNA were kindly provided by
Dr. Darryl Zeldin (NIEHS). Human heart, brain, and skeletal muscle
total RNA was purchased from ClonTech. Total RNA from HeLa S3 and
CEM-C7 cells was isolated using TRIzol Reagent (Life Technologies,
Inc.) according to the manufacturer’s instructions. cDNA was prepared
in a buffer containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 mMMgCl2,
1 mM each dGTP, dATP, dTTP, and dCTP, 20 units RNase inhibitor, 50
units murine leukemia virus reverse transcriptase, 2.5 mM random
hexamers, 1.0 mg of sample RNA, in a final volume of 20 ml. This
mixture was incubated for 10 min at RT, 15 min at 42 °C, and 5 min at
99 °C and then used for amplification of specific cDNAs by PCR. The
buffer for PCR contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM
MgCl2, 2.5 units AmpliTaq DNA polymerase, 0.2 mM upstream and
downstream primers, in a final volume of 100 ml. After an initial
incubation for 1 min at 95 °C, samples were subjected to 45 cycles of 30
s at 95 °C, 30 s at 62 °C, and 30 s at 72 °C. This was followed by a final
extension step at 72 °C for 10 min. The primers used for the amplifica-
tion of the 7.0-kb hGR message were as follows: 59-GCATTCATACAG-
GCAGCGAT-39 (upstream) and 59-CCACGTATCCTAAAAGGGCAC-39
(downstream) corresponding to nucleotides 4221–4240 and 2503–2523
of the hGRa and hGRb cDNAs, respectively (1). The primers used for
the amplification of the hGRa message were as follows: 59-CCTAAG-
GACGGTCTGAAGAGC-39 (upstream) and 59-GCCAAGTCTTGGC-
CCTCTAT-39 (downstream), corresponding to nucleotides 2158–2178
and 2616–2635 of the hGRa cDNA (1). The primers used for the am-
plification of the hGRb message were as follows: 59-CCTAAGGACG-
GTCTGAAGAGC-39 (upstream) and 59-CCACGTATCCTAAAAGGG-
CAC-39 (downstream), corresponding to nucleotides 2158–2178 and
2503–2523 of the hGRb cDNA (1). Amplified DNA fragments were
electrophoretically fractionated on 1.75% agarose gels. Restriction en-
zyme analysis of the RT-PCR products amplified by the hGRa- and
hGRb-specific primers confirmed that these fragments contained the
appropriate hGRa and hGRb cDNA sequences. Restriction enzymes
employed included NsiI (specific to exon 8), SspI (specific to exon 9a),
and HaeII (specific to exon 9b).
Quantitative RT-PCR—Human RNA (0.5 mg) was reverse tran-
scribed, and the resulting cDNA was amplified as described above. 5 ml
of the PCR reaction was removed at 2-cycle intervals and electrophor-
esed on 1.75% agarose gels stained with ethidium bromide. The inten-
sity of the ethidium bromide fluorescence was measured densitometri-
cally and plotted as a function of cycle number to generate amplification
curves for the hGRa and hGRb PCR fragments. Regression equations of
the form y 5 a 3 bn, where y is the intensity and n is the number of
cycles, were fitted to the data in the linear portion of the semi-logarith-
mic graphs. The amplification efficiencies (E) for the hGRa and hGRb
fragments, while nearly identical within tissues, varied slightly across
tissues: Ea 5 0.71 and Eb 5 0.71 for CEM-C7 cells but Ea 5 0.82 and
Eb 5 0.81 for human lung. Amplification curves were also generated
(and regression equations fitted) for external standards containing lin-
earized pCMVhGRb and pCMVhGRa at ratios of 1:1000, 10:1000, 100:
1000, and 1000:1000, respectively. A standard curve was generated by
plotting the difference in the number of cycles required to amplify
(during the exponential phase of each reaction) an identical amount of
the hGRa and hGRb PCR products (3000 densitometric units) as a
function of the pCMVhGRb/pCMVhGRa ratio. Similarly, the difference
in the number of cycles required to amplify (during the exponential
phase of each reaction) the same amount of hGRa and hGRb PCR
products (3000 densitometric units) for each human sample was calcu-
lated. Using the standard curve regression equation, the approximate
hGRb/hGRa cDNA (and hence mRNA) ratio was determined for each
human tissue and cell line.
Sucrose Density Gradients and Western Blots—Subconfluent COS-1
cells (4 3 106) were transfected by the calcium phosphate method as
described above with equimolar amounts of pCMVhGRa (40 mg), pCM-
VhGRb (36.4 mg), or pCMV5 (20.4 mg). Each transfection was standard-
ized to 40 mg of DNA using pBR322. Cells were harvested 48 h post-
transfection, resuspended in unsupplemented Dulbecco’s minimum
essential medium containing 100 nM [3H]DEX or 20 nM [3H]RU486, and
incubated for 2 h on ice with gentle agitation. Whole cell extracts were
prepared and processed on sucrose density gradients essentially as
described by Tully and Cidlowski (24). To verify equivalent expression
of the hGRa and hGRb proteins, an aliquot of each extract was analyzed
by Western blotting. Proteins (125 mg) were resolved by electrophoresis
through 7.5% polyacryalmide gels and electrophoretically transferred
to nitrocellulose. After incubating the membrane with epitope-purified
polyclonal anti-hGR antiserum #57 (25) at a dilution of 1:2000, immu-
noreactivity was visualized using enhanced chemiluminescence accord-
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ing to the manufacturer’s instructions (ECL, Amersham Corp.).
Immunohistochemistry—Subconfluent COS-1 cells (2 3 105) were
transfected with equimolar amounts of pCMVhGRa (20 mg) or pCM-
VhGRb (18.2 mg) by the calcium phosphate method as described above
or by the DEAE method of Sompayrac and Danna (26) as modified by
Gorman (27). Each transfection was standardized to 20 mg of DNA
using pBR322. Following transfection, the cells were incubated for 24 h
in Dulbecco’s minimum essential medium supplemented with 10% dex-
tran-coated charcoal-treated serum before plating in two-chamber glass
slides. After an additional 24-h incubation, transfected cells were
treated for 2 h with DEX (100 nM) or control vehicle and processed for
immunohistochemical staining as described previously (25). Immuno-
reactivity was visualized by staining with avidin-biotin-peroxidase or
Texas red fluorescent dye.
CAT Activity—Subconfluent COS-1, CV-1, and HeLa S3 cells were
transfected as indicated in the appropriate figure legends by the cal-
cium phosphate method described above. 16 h post-transfection, me-
dium was removed and replaced with control medium or medium con-
taining DEX or RU486. Cells were harvested 24 h later and CAT assays
were performed as described previously (22).
RESULTS
Northern Blot Analysis of the hGRb Message in Human Tis-
sues and Cell Lines—Northern blot analysis of RNA isolated
from various human cell lines routinely shows multiple hGR
mRNA transcripts approximately 7.0 and 5.0 kb in size (1,
28–33). These transcripts are thought to arise from the use of
alternative polyadenylation signals within the 39UTR of exon
9a and are presumed to encode the hGRa isoform. Because
early studies utilized probes that recognized a region common
to the hGRa and hGRb messages, one or more of these tran-
scripts might actually be the hGRb splice variant. In order to
discriminate between hGRa and hGRb messages and to assess
the relative amounts of these transcripts in a given tissue, we
sequentially hybridized poly(A)1 RNA isolated from various
human adult and fetal tissues with hGRb- and hGRa-specific
cRNA riboprobes. The hGRb riboprobe was designed to recog-
nize a 578-nucleotide segment spanning the coding and proxi-
mal 39 noncoding regions of exon 9b. The hGRa riboprobe was
designed to recognize a 534-nucleotide segment in the distal
39UTR of exon 9a.
As shown in Fig. 1A (upper and lower panels), the hGRb
probe hybridizes with an abundant message in all tissues mi-
grating slightly below the 7.5-kb RNA marker. Additionally, a
faint band slightly below the 4.4-kb RNA marker is observed in
the adult heart, brain, placenta, lung, liver, skeletal muscle,
and pancreas RNA samples and in the fetal brain, lung, and
liver RNA samples. The length of the hGRb cDNA predicts the
hGRb message to be at least 4.1 kb in size, thus the lower
hybridization signal (approximately 4.3 kb in size) may corre-
spond to the hGRb mRNA transcript. In contrast to the lower
hybridization signal, the abundant message approximately 7.0
kb in size cross-reacts with the hGRa riboprobe (Fig. 1B, upper
and lower panels). The hGRa riboprobe also hybridizes with a
message approximately 5.5 kb in size in many tissues and with
a less abundant 4.4 kb message in several tissues, and these
two transcripts do not appear to cross-react with the hGRb
probe (Fig. 1B, upper and lower panels). Finally, the hGR
mRNA transcripts approximately 7.0, 5.5, and 4.3 kb in size are
all recognized by a probe made to the common coding region of
the hGRa and hGRb cDNAs (data not shown). Similar hybrid-
ization patterns are also observed on Northern blots of RNA
isolated from HeLa S3 cells (a human cervical carcinoma cell
line) and CEM-C7 cells (a human lymphoid cell line) (data not
shown).
Characterization of the 7.0-kb hGR Message—Because the
7.0-kb hGR message is recognized by both the hGRa and hGRb
riboprobes, it must contain information from both the 9a and
9b exons. These exons, therefore, do not appear to be mutually
exclusive as previously reported (2). This observation made it
important to determine whether the 7.0-kb message encodes
the hGRa or hGRb isoform. Various data suggested that it
would encode hGRa. Exon 9a precedes exon 9b in the linear
organization of the hGR gene (2). If this order is maintained in
the mature message, exon 9a would form the distal coding and
proximal 39 noncoding regions, and exon 9b would comprise the
distal 39 noncoding region. A hGR message with this arrange-
ment at its 39 end would be expected to encode the hGRa
protein. Sequence conservation between hGR exons 9a and 9b
(as well as the 155-bp intron separating these two exons) and
the distal coding and 39 noncoding regions of the 6.5-kb rat GR
message (Fig. 2A) further suggested that the 7.0-kb hGR
mRNA transcript contains (moving 59 to 39) exon 9a, intron J,
and exon 9b sequences at its distal 39 end. If all 10 exons and
intron J of the hGR gene are represented in a mature hGR
message, this message would be approximately 6.8 kb in size,
consistent with the size of the hybridization signal observed on
our Northern blots.
To test whether the 39 end of the 7.0-kb hGR message is
organized in this fashion, we performed RT-PCR using a sense
59 primer specific to the distal 39UTR of exon 9a and an anti-
sense 39 primer specific to the proximal 39UTR of exon 9b. If the
39 end of the 7.0-kb hGR message consists of sequences from
exon 9a, intron J, and exon 9b, these primers will amplify a
933-bp PCR product. When total RNA extracted from HeLa S3
cells is used for RT-PCR, a PCR product of this size is generated
(Fig. 2B, lane 2). The PCR fragment is not produced when the
reverse transcriptase is omitted from the reaction, demonstrat-
ing that contaminating DNA is not present (Fig. 2B, lane 1). In
FIG. 1. Northern blot analysis of hGR messages in human
adult (upper panel) and fetal (lower panel) tissues. Human adult
and fetal multiple tissue Northern blots containing 2.0 mg of poly(A)1
RNA were hybridized with the hGRb-specific riboprobe (A, both panels).
The blots were then stripped and rehybridized with the hGRa-specific
riboprobe (B, both panels). RNA size markers are indicated along the
left margin, and the approximate sizes of the hybridization signals are
indicated along the right margin.
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addition, restriction enzymes that cleave sites specific to exon
9a, intron J, and exon 9b were used to confirm the sequence of
the 933-bp PCR fragment (Fig. 2B, lanes 3–5). Therefore, exon
9a makes up the distal coding and proximal 39 noncoding
regions of the 7.0-kb hGR message and both intron J and exon
9b form the distal 39 noncoding region of the 7.0-kb hGR mes-
sage. This message would be expected to encode the hGRa
isoform.
These RT-PCR results also demonstrate that sequences pre-
viously identified as intron J (2) are actually exonic sequences
separating the 9a and 9b exonic sequences. In agreement with
this finding, an oligonucleotide probe specific to intron J hy-
bridizes on Northern blots with the 7.0-kb hGRa message (data
not shown). Therefore, we propose that the hGR sequences
formerly identified as exon 9a, intron J, and exon 9b comprise
one large terminal exon (exon 9) approximately 4.1-kb in size
and that the hGR gene is organized into nine exons rather than
the previously reported ten (2).
RT-PCR Analysis of the hGRb Message in Human Tissues
and Cell Lines—The hGRb-specific riboprobe also hybridizes
with a faint message approximately 4.3 kb in size on the North-
ern blots shown in Fig. 1. The size of this message suggests that
it might be the hGRb mRNA transcript. However, because the
7.0-kb hGRa message contains the 9b sequences at its 39 end,
the 4.3-kb signal might instead be a degradation product of the
7.0-kb hGRa message. Alternatively, the 4.3-kb signal might
represent nonspecific hybridization of the hGRb probe with 28
S rRNA. Recently, it was reported using RT-PCR that the
alternative splicing event underlying the formation of the
hGRb mRNA transcript occurs in many different human tis-
sues (17). However, these experiments employed a very large
number of PCR cycles, and these workers apparently did not
control for potential amplification of contaminating DNA.
Therefore, to confirm that the hGRb message is expressed, we
performed RT-PCR on RNA isolated from various human tis-
sues and cell lines using primers that hybridize on either side
of the alternatively spliced region of the 4.3-kb hGRb message.
A sense 59 primer specific to exon 8 and an antisense 39
primer specific to the 9b sequences were utilized in the PCR
reaction. If the alternative splicing event underlying the for-
mation of the 4.3-kb hGRb message occurs (in which the end of
exon 8 is linked to the 9b sequences located in the distal portion
of exon 9) the hGRb-specific primers will produce a PCR prod-
uct 366-bp in length. If these primers hybridize with the 7.0-kb
hGRa message (which also contains the 9b sequences at its far
39 end), they will generate a PCR product approximately 3000
bp in length. Conditions of our PCR amplification reaction did
not favor production of this large PCR fragment, and it was
never observed. For parallel analysis of the hGRa mRNA tran-
scripts, an antisense 39 primer specific to the 9a sequences was
used in combination with the same sense 59 primer. If the
default splicing event underlying the formation of the hGRa
messages occurs (in which the end of exon 8 is linked to the 9a
sequences at the beginning of exon 9) these hGRa-specific
primers will produce a PCR product 477 bp in length.
When total RNA extracted from human heart, brain, lung,
liver, and skeletal muscle is used for RT-PCR, a 366-bp PCR
product is generated by the hGRb-specific primers, suggesting
that the hGRb message is present in these human tissues
(Fig. 3A). In addition, the hGRa-specific primers amplify the
expected 477-bp PCR product in each tissue (Fig. 3B). When
the reverse transcriptase is omitted from the RT-PCR reaction,
the expected PCR fragments are not produced, indicating that
only cDNA produced by the RT step is serving as template for
the correctly sized PCR product. RT-PCR analysis was also
performed on RNA isolated from HeLa S3 and CEM-C7 cells
(Fig. 3, A and B). Again, a 366-bp PCR fragment is produced by
the hGRb-specific primers, suggesting that the hGRb message
is present in these transformed human cell lines. Consistent
with our Northern blot data, the hGRb message appears to
have a widespread tissue distribution.
Together, the Northern blot and RT-PCR analyses indicate
that the hGR mRNA heterogeneity observed in human tissues
and cell lines includes both hGRa and hGRb messages. The
more abundant transcripts are approximately 7.0 and 5.5 kb in
size and are expected to encode the hGRa isoform. Consensus
polyadenylation signals are located at the end of the 9a se-
quences in exon 9, and use of these signals would generate a
hGRa message approximately 1.6 kb shorter than the full-
length 7.0-kb hGRa message. These consensus signals are
functional because they terminate transcription of the hGRa
cDNA cloned into an expression vector lacking other poly-
adenylation signals (data not shown). Therefore, the 5.5-kb
hGRa message appears to originate from alternative poly-
adenylation at these consensus sites. The less abundant hGR
message recognized by the hGRb-specific probe and approxi-
FIG. 2. Comparison of hGR exons 9a and 9b and intron J with
the rat GR cDNA (A) and RT-PCR analysis of the 7.0 kb hGR
message (B). A, using the sequence comparison program BestFit (Se-
quence Analysis Software Package, Genetics Computer Group, Univer-
sity of Wisconsin Biotechnology Center) (34), the hGRa cDNA se-
quences 2156–2313 (exon 8), 2314–2466 (exon 9a coding), and 2467–
4788 (exon 9a 39UTR) (1); intron J sequences 1–155 (2); and the hGRb
cDNA sequences 2314–2361 (exon 9b coding) and 2362–3791 (exon 9b
39UTR) (1) were aligned with the rat GR cDNA sequences 1–6322 (35).
The regions of greatest similarity and the percentage of identity be-
tween the two aligned sequences are indicated. Triangles identify con-
sensus polyadenylation signals, and arrows indicate the location of PCR
primers utilized in B. B, total RNA (1.0 mg) from HeLa S3 cells was
reverse transcribed using random hexamers, and first strand cDNA
was subsequently amplified with the addition of an upstream primer
specific to the distal 39UTR of exon 9a and a downstream primer
specific to the proximal 39UTR of exon 9b. The resulting RT-PCR
products were then analyzed by agarose gel electrophoresis. The re-
verse transcriptase was omitted in lane 1 but included in lane 2. In
lanes 3–5, the PCR product was digested with restriction enzymes that
cut specifically in exon 9a (Acc65I), intron J (HpaII), or exon 9b (HaeII).
Sizes (in bp) of DNA markers (M) are indicated in the left margin.
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mately 4.3 kb in size is expected to encode the hGRb isoform.
This mRNA transcript results from alternative splicing in
which a 39 acceptor site preceding the 9b sequences in exon 9 is
utilized by the splicing machinery rather than the normal 39
acceptor site preceding the 9a sequences in exon 9. The model
shown in Fig. 4 summarizes the predicted structure at the 39
end of the hGR gene, primary transcript, and mature hGRa
and hGRb mRNAs; the processing events underlying the for-
mation of these mature messages; and the predicted transla-
tion products of these transcripts.
Based on the intensity of the Northern blot signals, the two
hGRa messages (7.0 and 5.5 kb) are much more abundant than
the 4.3-kb hGRb message (see Fig. 1). To more accurately
assess the relative levels of the hGRa and hGRb mRNA tran-
scripts, we performed quantitative RT-PCR on RNA isolated
from adult lung, adult liver, HeLa S3 cells, and CEM-C7 cells.
Reaction cycle intensity curves for the 477-bp hGRa and 366-bp
hGRb PCR products are shown for each tissue and cell line in
Fig. 5A. For estimation of the hGRb/hGRa mRNA ratio, regres-
sion equations were fitted to the linear portion of each ampli-
fication curve, and the difference in the number of cycles re-
quired to amplify an equal amount of hGRa and hGRb PCR
product was calculated. Similarly, the difference in cycle num-
ber required to amplify an equal amount of hGRa and hGRb
PCR product was determined for a series of external standards
containing known hGRb/hGRa cDNA ratios. Using the stand-
ard curve shown in Fig. 5B, the hGRb/hGRa cDNA (and hence
mRNA) ratio for each human sample was calculated and is as
follows: 0.34% for lung, 0.21% for liver, 0.21% for HeLa S3 cells,
and 0.22% for CEM-C7 cells. Although these values reflect a
large difference in expression levels, one should bear in mind
that the amount of the 477-bp hGRa fragment is derived from
two hGRa messages (7.0 and 5.5 kb), whereas the amount of
366-bp hGRb fragment comes only from the 4.3-kb hGRb mes-
sage. In addition, our approach assumes that the efficiency of
the RT reaction is the same for both the hGRa and hGRb
mRNA transcripts. This may not be the case.
Ligand Binding Analysis of hGRb—Operating under the
FIG. 3. RT-PCR analysis of RNA isolated from human tissues
and cell lines using hGRb- and hGRa-specific primers. Total RNA
(0.5 mg) isolated from various human adult tissues (heart, brain, lung,
liver, and skeletal muscle) and cell lines (HeLa S3 and CEM-C7 cells)
was reverse transcribed using random hexamers. The resulting cDNA
was amplified using either hGRb-specific (A) or hGRa-specific (B) prim-
ers. For each set of primers, the reverse transcriptase was omitted in
lanes 2, 4, 6, 8, 10, 12, and 14 but included in lanes 3, 5, 7, 9, 11, 13, and
15. No RNA was added in lane 1. The RT-PCR products were analyzed
by agarose gel electrophoresis. The sizes (in bp) of the DNAmarkers (M)
are 603, 310, 281/271, 234, and 194).
FIG. 4. Predicted structure of the hGR gene and gene products. hGR sequences formerly identified as exon 9a, intron J, and exon 9b
comprise one large exon (exon 9). Alternative processing of exon 9 generates multiple hGRmessages. Specifically, splicing event #1 (default splicing
pathway) in which the end of exon 8 is linked to beginning of exon 9 is predicted to generate the 7.0- and 5.5-kb hGRa messages, which differ in
size due to the use of alternative polyadenylation signals. Splicing event #2 (alternative splicing pathway) in which the end of exon 8 is linked to
the beginning of the 9b sequences is predicted to generate the 4.3-kb hGRb message. Translation of the messages produces the hGRa and hGRb
isoforms, which are identical through amino acid 727 but then diverge. The functional domains and the putative site of hsp90 interaction are
indicated for each isoform. Exons and introns (not to scale) are designated by boxes and lines, respectively. The arrows along the primary transcript
identify the location of consensus polyadenylation signals. Splicing of introns A–G is not shown. The hGRa- and hGRb-specific cRNA probes used
in this study are indicated by solid lines.
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assumption that the endogenous hGRb message is translated
into the endogenous hGRb protein, we began investigating the
biochemical properties of hGRb when overexpressed in trans-
fected COS-1 cells. COS-1 cells contain undetectable levels of
endogenous GR (3) and therefore provide a model system for
studying the biochemical properties of hGRb in the absence of
hGRa. The carboxyl-terminal 50 amino acids of hGRa have
been replaced in hGRb with 15 unique amino acids. To inves-
tigate the effect this has on the ability of hGRb to bind hormone
or antihormone, we transfected COS-1 cells with a hGRa ex-
pression vector (pCMVhGRa), a hGRb expression vector (pC-
MVhGRb), or the expression vector backbone (pCMV5). The
FIG. 5. Quantitative RT-PCR analysis of hGRa and hGRb mes-
sages. A, human RNA (0.5 mg) was reverse transcribed, and the result-
ing cDNA amplified using hGRa- or hGRb-specific primers. Aliquots of
the PCR reaction were removed at 2-cycle intervals and electrophoresed
on agarose gels stained with ethidium bromide. Representative gels
showing amplification of the 477-bp hGRa and 366-bp hGRb fragments
are from human lung (upper panel). By plotting ethidium bromide
fluorescence as a function of cycle number, hGRa and hGRb amplifica-
tion curves were generated for adult lung, adult liver, HeLa S3 cells,
and CEM-C7 cells (lower panel). B, standard curve showing the rela-
tionship between a known hGRb/hGRa cDNA ratio and the additional
number of cycles required by the hGRb primers to amplify as much PCR
product as the hGRa primers. “Cycle number difference” calculations
are from the exponential phase of each PCR reaction and are described
under “Experimental Procedures.” For each human tissue and cell line,
the standard curve regression equation y 5 24.427LOG(x) 1 0.297 (r 5
0.994) was used to determine the hGRb/hGRa cDNA (and hence mRNA)
ratio.
FIG. 6. In vivo ligand binding analysis of hGRb expressed in
transfected COS-1 cells. A, COS-1 cells were transfected with
equimolar amounts of pCMVhGRa, pCMVhGRb, or pCMV5 (mock) as
described under “Experimental Procedures” and incubated with 100 nM
[3H]dexamethasone (upper panel) or 50 nM [3H]RU486 (lower panel) for
2 h on ice. Whole cell extracts were prepared and loaded on 5–20%
sucrose gradients. Following centrifugation, the gradients were frac-
tionated, and radioactivity was determined. B refers to the bottom of
the gradient, and T refers to the top. B, a portion of each whole cell
extract was analyzed by Western blotting using the anti-hGR antibody
#57 (25) that recognizes an epitope common to the 94-kDa hGRa and
90-kDa hGRb proteins. Molecular mass standards are indicated in the
left margin.
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cells were incubated with radiolabeled DEX, a synthetic glu-
cocorticoid agonist, or radiolabeled RU486, a synthetic glu-
cocorticoid antagonist. [3H]Steroid-receptor complexes formed
in vivo were then analyzed by sucrose density gradients. Show-
ing the standard sedimentation profile for the 8 S unactivated
GR (24), hGRa binds both [3H]DEX and [3H]RU486 (Fig. 6A).
In contrast, hGRb does not appear to bind either of these
ligands, because the sedimentation profiles for the pCM-
VhGRb- and pCMV5-transfected cells are superimposable.
Western blot analysis of the extracts analyzed for hormone
binding demonstrates that both the 94-kDa hGRa and 90-kDa
hGRb isoforms were synthesized at similar levels (Fig. 6B).
Therefore, lack of steroid binding by hGRb is not due to insuf-
ficient expression of the hGRb protein. Interestingly, the hGRa
expression vector does not contain the hGRb-specific se-
quences, yet a 90-kDa protein is observed in the pCMVhGRa-
transfected cells (Fig. 6B). This protein, which cannot be hGRb,
appears to be a degradation product or post-translational mod-
ification of the 94-kDa hGRa isoform.
Subcellular Distribution of hGRb—Numerous studies have
shown that hGRa resides in the cytoplasm of cells in the ab-
sence of hormone and translocates to the nucleus in a hormone-
dependent manner (11). To determine where hGRb is localized
within a given cell, COS-1 cells were transiently transfected
with the hGRa or hGRb expression vectors. The plasmids were
delivered into the cells using either the DEAE-dextran or cal-
cium phosphate transfection method to rule out potential arti-
facts due to the transfection procedure. After treating the cells
for 2 h with or without DEX, immunohistochemistry was per-
formed, and immunoreactivity was visualized by staining with
Texas red fluorescent dye or avidin-biotin-peroxidase. In the
absence of hormone hGRa is found in the cytoplasm of the
transfected cells, but following hormone administration it
translocates and becomes predominantly nuclear (Fig. 7, left
panel). In contrast, the hGRb protein resides primarily in the
nucleus of the transfected cells independent of hormone treat-
ment (Fig. 7, right panel). These findings were consistent re-
gardless of the transfection method or immunohistochemical
staining procedure employed.
Transcriptional Activity of hGRb in the Absence of hGRa—
hGRb does not appear to bind hormone or antihormone, but it
resides primarily in the nucleus of transfected COS-1 cells (and
CV-1 cells)2 and has been reported to bind a consensus GRE in
vitro (17). Therefore, we investigated the ability of hGRb to
activate or repress the glucocorticoid-responsive MMTV en-
hancer in the presence or the absence of steroid. For these
experiments, COS-1 cells were cotransfected with an MMTV-
CAT reporter plasmid (pGMCS) and either pCMV5, pCM-
VhGRa, or pCMVhGRb. In response to DEX, hGRa induces a
4-fold increase in CAT expression over that observed in the
vehicle-treated cells, whereas RU486 alone has little or no
effect (Fig. 8A, lanes 4–6). In contrast, CAT expression is
unchanged in the hGRb-containing cells treated with steroid,
which is consistent with the inability of hGRb to bind these
ligands (Fig. 8A, lanes 7–9). Moreover, hGRb does not appear to
be constitutively active as an enhancer or repressor because
levels of CAT activity in the vehicle-treated cells are similar
whether they contain the CMV-vector backbone or pCMVhGRb
(Fig. 8A, compare lanes 1 and 7).
The hGRa-mediated induction of CAT activity in transfected
COS-1 cells was only 4-fold. In cell lines where hGRa induc-
tions are much greater, hGRb might display partial transcrip-
tional activity. Therefore, we investigated the transcriptional
activity of hGRb on the MMTV enhancer in receptor negative
CV-1 cells. In response to DEX, hGRa induces a 74-fold in-
crease in CAT expression (Fig. 8B, lanes 4 and 5). Interest-
ingly, hGRa induces a 29-fold increase in CAT expression in
response to RU486 (Fig. 8B, lanes 4 and 6). This partial agonist
activity of RU486 has been reported previously and appears to
be cell type-specific (37). Consistent with our findings in COS-1
cells, CAT expression is unchanged in CV-1 cells transfected
with hGRb and treated with steroid (Fig. 8B, lanes 7–9). In
addition, hGRb does not appear to be constitutively active (Fig.
8B, compare lanes 1 and 7). Thus, we conclude that in the
absence of hGRa, hGRb is transcriptionally inactive on the
glucocorticoid-responsive MMTV enhancer.
Transcriptional Activity of hGRb in the Presence of
hGRa—In the absence of hGRa, hGRb is unable to directly
enhance or repress transcription of the MMTV-CAT reporter
plasmid. To determine if hGRb influences gene expression in-
directly by modulating the transactivation capacity of hGRa,
HeLa S3 cells (which contain approximately 20,000 hGRa re-
ceptors per cell) were cotransfected with pGMCS and various
2 R. H. Oakley and J. A. Cidlowski, unpublished observations.
FIG. 7. Subcellular distribution of
hGRb expressed in transfected
COS-1 cells. COS-1 cells were trans-
fected with equimolar amounts of pCM-
VhGRa (left panel) or pCMVhGRb (right
panel) using either the DEAE or calcium
phosphate (CaPO4) transfection methods
as described under “Experimental Proce-
dures.” 36 h post-transfection, cells were
treated for 2 h with vehicle (2Dex) or with
100 nM DEX (1Dex). Immunohistochem-
istry was then performed using the anti-
hGR antibody #57 (25), and immunoreac-
tivity was visualized by staining with
Texas red fluorescent dye (left side, each
subpanel) or avidin-biotin-peroxidase
(right side, each subpanel).
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amounts of pCMVhGRb (Fig. 9A). When pGMCS alone is trans-
fected into the cells, DEX treatment results in a 50-fold induc-
tion of CAT activity. However, as increasing amounts of pCM-
VhGRb are transfected into the cells, the glucocorticoid-
induced, hGRa-mediated activation of the MMTV enhancer is
repressed in a dose-dependent manner. We observe a 78 and
96% inhibition of CAT expression when 1.0 and 3.0 mg, respec-
tively, of pCMVhGRb is used in the transfection mixture.
Transfection of a 2-fold molar excess of the CMV-vector back-
bone (pCMV5) has no effect on hGRa-mediated induction of
CAT expression, indicating that hGRb is responsible for the
repression.
We next evaluated whether the dominant negative activity of
hGRb on hGRa-mediated transcription is restricted to the
MMTV promoter or is a general property of glucocorticoid-
responsive promoters. The pGRE2CAT reporter plasmid con-
tains two copies of the GRE consensus sequence derived from
the tyrosine aminotransferase gene and a TATA box element
upstream of the CAT gene (20). In contrast to MMTV, this
“minimal promoter” does not contain binding sites for other
ancillary transcription factors. When HeLa S3 cells are cotrans-
fected with pGRE2CAT and various amounts of pCMVhGRb
(Fig. 9B), the hGRa-mediated stimulation of CAT expression is
inhibited in a dose-dependent manner, and the repression of
hGRa activity is similar to that observed on the MMTV pro-
moter. The inhibitory action of hGRb is restricted to glucocor-
ticoid-responsive promoters because the hGRb protein has no
effect on the constitutively active, nonglucocorticoid-responsive
thymidine kinase CAT reporter plasmid (pBLCAT2) (data not
shown). In sum, these results suggest that hGRb represses the
function of hGRa by specifically inhibiting GRE-mediated
transcription.
DISCUSSION
Alternative splicing of the hGR primary transcript produces
two highly homologous isoforms, termed hGRa and hGRb,
which differ at their carboxyl termini (1, 2). In contrast to the
well characterized hGRa isoform, very little is known about the
hGRb splice variant. In this report, we examine the expression,
biochemical properties, and physiological function of hGRb.
Northern blot analysis with a hGRb-specific riboprobe demon-
strates the presence of a message approximately 4.3 kb in size
(consistent with the length of the hGRb cDNA) in many differ-
ent human tissues. We subsequently confirmed by RT-PCR
that the alternative splicing event proposed to underlie the
formation of the hGRb mRNA transcript occurs in these tissues
as well as in several transformed human cell lines. Together,
these results indicate that the hGRb message is endogenous to
a variety of cells. Because both the hGRa and hGRb messages
are co-expressed in many of the same tissues, previous studies
investigating hGRa expression with probes that did not dis-
criminate between hGRa and hGRb may be in error. The hGRb
mRNA transcript generated in vivo from the pCMVhGRb ex-
pression vector is efficiently translated into the 90-kDa hGRb
protein in transfected COS-1, CV-1, and HeLa S3 cells, suggest-
FIG. 8. Transcriptional activity of hGRb in the absence of
hGRa. COS-1 (A) or CV-1 (B) cells were cotransfected with pGMCS (5.0
mg) and equimolar amounts of pCMV5 (2.8 mg), pCMVhGRa (5.5 mg), or
pCMVhGRb (5.0 mg). Each transfection was standardized to 10.5 mg of
DNA using pBR322. 16 h post-transfection, medium containing vehicle
(CON), 100 nM DEX, or 1 mM RU486 was added to the cells, which were
then incubated an additional 24 h. Cells were then harvested, and CAT
activity was determined. The data are plotted as fold change from basal
activation (pCMV5, CON). A shows the average of three independent
experiments, and B is representative of three independent experiments.
FIG. 9. Transcriptional activity of hGRb in the presence of
hGRa. HeLa S3 cells were cotransfected with 5.0 mg of pGMCS (A) or
pGRE2CAT (B) and various amounts of pCMV5 and pCMVhGRb as
indicated. 16 h post-transfection, medium containing vehicle (CON) or
100 nM DEX was added to the cells, which were then incubated an
additional 24 h. Cells were then harvested, and CAT activity was
determined. The data are plotted as fold change from basal activation
and are representative of three independent experiments.
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ing that the endogenous hGRb message can also serve as a
template for protein synthesis. However, whether the endoge-
nous hGRb message is actually translated into the hGRb iso-
form is unknown. Anti-hGR antibodies made to date in several
different laboratories have epitopes in the amino terminus and
thus recognize both the hGRa and hGRb proteins. The small
difference in size between the two isoforms and the potential
for hGRa to be post-translationally modified or degraded into a
smaller protein make this cross-reactivity undesirable. To test
directly for the expression of the hGRb protein, we are pres-
ently making a hGRb-specific antibody.
During our investigation of the expression of the hGRb mes-
sage, we made several observations that provide new insights
both into the structure of the hGR gene and hGRa mRNAs and
into the expression of the hGRa messages. The hGR gene has
been previously reported to consist of 10 exons (2). Results from
our Northern blot and RT-PCR analyses suggest that the last
two exons, 9a and 9b, and the intronic sequences separating
these two exons (intron J) together form one large terminal
exon (exon 9). Exon 9 encodes the 39 end of the hormone-
binding domain of the hGRa protein (under normal splicing
conditions) and contains approximately 4.0 kb of 39UTR. It is
interesting to note that the genes for the human androgen
receptor, human estrogen receptor, and chicken progesterone
receptor show a similar organization to that we have proposed
here for the hGR. In each case, the most 39 exon (exon 8)
encodes the COOH-terminal portion of the hormone-binding
domain and specifies a very large 39UTR (38–42). The differ-
ential hybridization of the hGRa- and hGRb-specific riboprobes
with the 7.0- and 5.5-kb hGRa messages suggests that they
originate from the use of alternative polyadenylation signals
located in the 4.0-kb 39UTR of exon 9. Similar alternative
polyadenylation events have been proposed to explain the GR
mRNA heterogeneity observed in rat tissues (35). Within the
39UTR of eukaryotic mRNA reside signals that influence
mRNA localization, mRNA stability, and translation initiation
(43, 44). The 7.0- and 5.5-kb hGRa messages may differ in one
or more of these properties. Both hGRa messages have a wide-
spread tissue distribution, although the 5.5-kb hGRa message
does not appear to be expressed at high levels in the brain. In
addition, the 7.0-kb message is consistently more abundant
than the 5.5-kb message.
The 7.0- and 5.5-kb hGRa messages are much more abun-
dant than the 4.3-kb hGRb mRNA transcript. Quantitative
RT-PCR analysis of RNA isolated from two adult tissues and
two human cell lines suggests that there is 200–500-fold more
hGRa. However, because alternative splicing is often regulated
in a spatial and/or temporal fashion, the hGRb message may be
expressed at higher levels in a tissue-specific and/or develop-
mental stage-specific manner. In addition, the hGRa/hGRb
mRNA ratio may or may not reflect the hGRa/hGRb protein
ratio due to potential differences in stability and/or translation
efficiency of the hGRa and hGRb messages and/or due to dif-
ferences in protein half-life. Furthermore, because the 7.0-kb
hGRa message has the 9b sequences at its far 39UTR, we
cannot exclude the possibility that it also encodes the hGRb
protein. Development of hGRa- and hGRb-specific antibodies
will provide insight into this issue. Interestingly, the 9b se-
quences are well conserved in the rat GR cDNA 39UTR, sug-
gesting that an hGRb homolog may exist in rat. RT-PCR anal-
ysis of rat liver (as well as a mouse lymphoma cell line) does
indeed produce a PCR product that comigrates with the 366-bp
PCR fragment derived from human cells.2 Thus, although the
hGRb message is expressed at low levels relative to the hGRa
mRNA transcripts in the human tissues so far examined, its
conservation across species suggests that it plays an important
physiological role.
With few exceptions (45, 46), modification of the GR hor-
mone-binding domain results in a reduction or complete loss of
hormone binding (3, 47–50). The COOH-terminal 50 amino
acids of hGRa have been replaced in hGRb with 15 unique
amino acids. In agreement with previous reports (1, 3, 17), we
show that this natural COOH-terminal modification prevents
agonist binding to the hGRb protein. Recently, it was reported
that a truncated version of the human progesterone receptor B
form missing the COOH-terminal 42 amino acids did not bind
progesterone or the synthetic agonist R5020 but still bound the
antiprogestin RU486 (51). This finding suggested that amino
acids at the extreme COOH terminus of the human progester-
one receptor are critical for agonist but not antagonist binding.
Because members of the steroid hormone receptor superfamily
share many of the same properties, we tested the ability of
hGRb to bind RU486 but found no evidence of binding. The 15
amino acids at the end of hGRb may prevent the association of
RU486 with this isoform. Alternatively, the observation made
for human progesterone receptor B form may not be conserved
among other family members. At this time, hGRb is more aptly
described as an orphan receptor whose natural ligand, if any, is
unknown.
The hGRa receptor isoform translocates from the cytoplasm
to the nucleus in a hormone-dependent manner (11). In the
absence of hormone, the association of hsp90 with hGRa ap-
pears to inactivate the NLS (52, 53). Once hormone binds
hGRa, hsp90 dissociates from the receptor resulting in the
activation of the NLS and subsequent nuclear import of hGRa
(8). In contrast to hGRa, we demonstrate that hGRb resides
primarily in the nucleus of transfected cells independent of
hormone treatment. The amino acids necessary for interacting
with hsp90 (7) are present in hGRb, suggesting that hGRb may
be in the nucleus in spite of its association with hsp90. Perhaps
the unique COOH-terminal amino acids of hGRb delete se-
quences that inhibit the NLS or slightly alter the tertiary
structure of the hGRb/hsp90 complex such that the NLS are
partially activated. This might account for our observation that
most, but not all, of the hGRb protein is located in the nucleus.
Further studies will be required to elucidate the precise mech-
anism(s) underlying the nuclear distribution of hGRb.
In the absence of hGRa, the hGRb isoform is transcription-
ally inactive on the MMTV enhancer independent of steroid
treatment. However, when hGRa and hGRb are expressed in
the same cell, hGRb inhibits the glucocorticoid-induced, hGRa-
mediated activation of the MMTV promoter. Although this
dominant negative effect was first reported in COS-7 cells
cotransfected with hGRa and hGRb expression vectors (17), we
have extended this initial observation in several respects.
First, we demonstrate that this dominant negative activity
occurs in cells that have endogenous hGRa receptors. In addi-
tion, we show that the repression of hGRa activity occurs with
the simple promoter pGRE2CAT. This indicates that the re-
pression is a general phenomenon of glucocorticoid-responsive
promoters and that it is GRE-mediated transcription that is
actually inhibited.
The mechanisms responsible for the hGRb-mediated repres-
sion of hGRa activity are unknown. The hGRb protein is pri-
marily located in the nucleus of transfected cells, has an intact
DNA-binding domain and has been reported to bind a consen-
sus GRE in vitro (17). Therefore, it may compete with hGRa for
binding to the GRE. Another possibility is that hGRb forms a
heterodimer with hGRa that is transcriptionally inactive or
less active than an hGRa homodimer. Alternatively, the hGRb
isoform may inhibit the function of hGRa by interacting with
and titrating out an essential cofactor needed by hGRa for full
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transcriptional activity. We are currently trying to identify the
mechanism(s) responsible for the dominant negative activity of
hGRb and to determine whether hGRb can inhibit hGRa-me-
diated repression of gene expression. Moreover, we hope to
discern if hGRb exhibits its dominant repressive effect on other
members of the closely related subgroup of nuclear receptors
that includes the progesterone, androgen, and mineralocorti-
coid receptors.
We have demonstrated that an alternatively spliced form of
the hGR is present in many different tissues and is able to
antagonize the physiological function of its predominant gene
product. Alternative splicing plays a critical role in regulating
the activity of several other members of the steroid/thyroid/
retinoic acid receptor superfamily. Most closely resembling
that observed for hGRa and hGRb is the processing that occurs
at the thyroid hormone receptor a subunit (TRa) locus. Alter-
native splicing of the last exon generates two receptor isoforms,
TRa1 and TRa2, that differ at the carboxyl terminus (36). The
TRa2 isoform does not bind thyroid hormones, but it represses
the transcriptional activity of TRa1 by competing with TRa1
for binding to the thyroid hormone receptor responsive ele-
ments (36). Clearly, the ability of steroid/thyroid/retinoic acid
receptor genes to encode transcription factors with opposing
biological activities adds another level of complexity to the
regulation of the function of these receptors.
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